11 results about "Endoderm" patented technology

The present disclosure provides methods of producing a population of endodermal stem cells (EnSC), a population of EnSC-derived PP cells, a population of EnSC-derived EP cells, or regenerative pancreatic islet tissue (E-islets). The disclosure also relates to EnSC, EnSC-derived PP cells, EnSC-derived EP cells or regenerated pancreatic islet tissue obtained using the method, and therapeutic uses thereof.

The invention relates to a construction method of a human haploid blastoid, which comprises the following steps: firstly, sorting haploid cells, and placing the haploid cells in a human blastoid induction system to generate a human haploid blastoid-like structure with haploid attributes, namely the human haploid blastoid; the constructed human haploid blastoid has a structure and cell composition similar to those of a human blastocyst, and human embryonic stem cell lines, human trophoblast stem cell lines and human extraembryonic endoderm stem cell lines can also be established in different cell induction culture solutions. The human haploid blastoid has the structure and function similar to those of a human blastocyst, also has the advantages of haploid cells, and can be used for research on generation of human haploid embryo related cell lines, genetic screening of human early embryonic development and the like.

The invention provides a construction method of a thyroid organoid derived from human induced pluripotent stem cells, and belongs to the technical field of organoid culture. The construction method of the thyroid organ comprises the following steps: (1) separating human induced pluripotent stem cells into single cells, and transferring the single cells to a 2D matrigel working solution for incubation; (2) carrying out endoderm induced culture on the cells incubated in the step (1); (3) carrying out preintestinal endoderm induced culture on the cells obtained in the step (2); (4) carrying out thyroid gland directional induction culture on the cells obtained in the step (3); (5) carrying out thyroid maturation induction culture on the cells obtained in the step (4) to obtain thyroid organs; naI with the final concentration of 0.8-1.2 [mu] M is added during thyroid maturation induction culture. The thyroid organoid constructed by the method is high in maturity, can simulate the state of the in-vivo organoid more truly, and has good capability of secreting thyroid-related hormones at the same time.

This invention relates to a method for inducing differentiation of human induced pluripotent stem cells (iPSCs) to establish liver organoids. The method includes: human iPSC culture, directed endoderm induction, foregut endoderm induction, FG cell 3D expansion, and liver organoid induction culture and maturation. This method overcomes the shortcomings of existing technologies. First, human iPSCs can be induced from human blood cells, skin cells, etc., solving the problem of cell source. Second, due to the pluripotency of iPSCs, liver organoids differentiated from iPSCs can generate liver organoids containing multiple cellular components. Furthermore, the method for generating organoids from iPSCs allows for gene editing and labeling of stem cells, and enables large-scale, standardized differentiation, thus possessing broad application prospects.

This disclosure provides thymocytes, thymic organoids, and animal models comprising such thymocytes and thymic organoids. It also provides methods for inducing the differentiation of pluripotent stem cells into endoderm (DE), anterior foregut endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial precursor (TEP) cells, thymic epithelial cells (TEC), and thymic organoids in vitro and in vivo.

The invention provides an efficient and repeatable stem cell-derived pancreatic beta cell preparation method, Wnt and Notch signal channels are regulated and controlled in stages, a culture environment is optimized in combination with bionic matrix stiffness, and differentiation of pluripotent stem cells to functional pancreatic beta cells is promoted. The method specifically comprises the following steps: 1, stage signal regulation: activating a Wnt pathway at the early stage of differentiation to promote endoderm induction, and then inhibiting a Notch pathway to enhance endocrine precursor cell formation; 2, bionic matrix rigidity optimization: adopting hydrogel (-1-5kPa) matched with natural pancreas islet rigidity to simulate an in-vivo microenvironment, and improving beta cell maturity and functions; 3, glucose responsiveness optimization: through later-stage low-glucose / high-glucose alternate culture, the glucose sensitivity of beta cells is enhanced, so that the insulin secretion amount is close to the primary cell level. According to the method, the yield and the function of the beta cells are remarkably improved, and a reliable cell source is provided for diabetes cell therapy.

This invention discloses a BSH fluorescent probe PET-CT nine-square grid method for determining boron concentration in cancer cells. Using a BSH fluorescent probe PET-CT instrument, tumor cells from the endoderm, mesoderm, and ectoderm are selected according to the nine-square grid theory, and then their IC50 and PET-CT values ​​are measured separately. The significance of this invention is to assist in achieving precise treatment with BNCT capture therapy, maximizing the therapeutic effect of BNCT therapy, and avoiding the ineffective treatment caused by clinicians and dosimeters misselecting boron drugs, thus preventing patients from undergoing repeated radiotherapy, increasing suffering, and extending treatment time and costs.

The invention relates to the use of a laminin (LN) matrix for hepatic differentiation. The invention also relates to a method for inducing hepatic differentiation comprising the steps of: (i) providing a population of human totipotent cells, (ii) culturing the population on a laminin-coated support in an endoderm stimulation medium to produce a population of human DE cells, (iii) culturing said population of human DE cells on a laminin-coated support in a hepatic stimulation medium to produce a population of human hepatoblast-like cells, and (iv) optionally culturing said population of human hepatoblast-like cells on a laminin-coated support in a hepatic maturation medium to produce a population of human hepatocyte-like cells.The invention further relates to a population of human hepatoblast-type cells or human embryonic hepatocyte-type cells obtained by the method of the invention. The invention further relates to a population of human hepatoblast-type cells expressing HNF4 α and expressing substantially AFP for use in a method of treating the human body.

Provided are a stem cell-derived gastruloid model, method for constructing same, and use thereof. The gastruloid model is constructed in vitro from human pluripotent stem cells, and simulated the biological events of early embryonic development and the key structures of the embryo to a certain extent, such as the development of primitive endoderm, the establishment of bilaminar germ disc, the appearance of the amniotic cavity and amniotic cells, and the appearance of the primitive streak and the like, which has been verified at both the protein level and the transcriptome level, and the key features of embryos from the peri-implantation period to the gastrula period could be well reproduced. This model can be induced in batches as a drug screening model for early embryos and environmental toxicants and the like, thereby providing safety testing for the use of drugs for certain clinical patients in early pregnancy and so on.

A construction method and use of a gastruloid stem cell line. Gastruloid stem cells that can be passaged stably are established in this research. The cells maintain the pluripotency of stem cells to a certain extent, exhibit gene and protein expression of cells from three germ layers, endoderm, mesoderm, and ectoderm, during gastrulation, and have characteristics consistent with those of cells during gastrulation, so that key characteristics of cells during gastrulation can be well reproduced. A three-dimensional gastruloid model that can mimic gastrulation can be constructed in mice or in vitro by using the stem cell line, and key biological events can be partially reproduced, so that key characteristics of post-implantation embryos during gastrulation can be well reproduced. Through this model, an in vitro platform for screening drugs affecting early embryonic development can be established, providing a reference for clinical medication.

The present invention discloses methods for producing induced pluripotent stem cell (iPSC)-derived hepatocytes and 3D liver organoids; methods for producing iPSC-derived endodermal progenitor intermediates including gut endodermal progenitors and hepatic endoderm progenitors; and methods for cryopreserving iPSC-derived endodermal progenitor intermediates, mature hepatocytes, and 3D liver organoids without the use of a ROCK inhibitor. By using embedding pluripotent stem cells (PSCs) in 3D scaffold in combination with a stepwise methodology that employs targeted induction cocktails specifically tuning the activation or inhibition of pathways including TGF-β, Wnt, BMP, retinoid acid, these methods streamline the differentiation of PSCs into high purity hepatocytes and 3D liver organoids which can be used for both diagnostic (e.g. drug toxicity screening) and therapeutic uses.